LRRK2 抗体 (AA 931-962)
(4 references)Quick Overview for LRRK2 抗体 (AA 931-962) (ABIN1882109)
抗原
See all LRRK2 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 931-962
-
纯化方法
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
免疫原
- This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).
-
亚型
- Ig Fraction
-
-
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 930-961) antibody
LRRK2 适用: 人, 小鼠 WB, ELISA, IF 宿主: 兔 Polyclonal unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 878-909) antibodyLRRK2 适用: 人, 小鼠 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 931-962) antibodyLRRK2 适用: 人 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 2171-2207), (C-Term) antibodyLRRK2 适用: 人 WB, IHC, FACS 宿主: 兔 Polyclonal RB50924 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 878-909) antibodyLRRK2 适用: 人, 小鼠 WB, IHC (p) 宿主: 兔 Polyclonal RB7207 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (AA 930-961) antibodyLRRK2 适用: 人, 小鼠 WB, IF 宿主: 兔 Polyclonal RB07209 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (C-Term) antibodyLRRK2 适用: 人, 小鼠 宿主: 小鼠 Monoclonal 133AT1218 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (C-Term) antibodyLRRK2 适用: 人, 小鼠 WB 宿主: 小鼠 Monoclonal 133AT720 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (C-Term) antibodyLRRK2 适用: 人, 小鼠 WB, ELISA 宿主: 小鼠 Monoclonal 133AT720 unconjugated
anti-Leucine-Rich Repeat Kinase 2 (LRRK2) (C-Term) antibodyLRRK2 适用: 人 WB, ELISA 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).
: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).
: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).
: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, (2004) (PubMed).
-
: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).
-
- LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))
-
别名
- PARK8 (LRRK2)
-
背景
- Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
-
分子量
- 286103
-
NCBI登录号
- NP_940980
-
UniProt
- Q5S007
-
途径
- Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development
抗原
-
